a 2008

Significance of molecular cytogenetic characterization of glioblastoma for prediction of patient prognosis

CEJPEK, Pavel, Petr KUGLÍK, Renata VESELSKÁ, Eva NEČESALOVÁ, Martina PEŠÁKOVÁ et. al.

Basic information

Original name

Significance of molecular cytogenetic characterization of glioblastoma for prediction of patient prognosis

Name in Czech

Význam molekulárně cytogenetické charakteristiky glioblastomu pro predikci prognozy nemocného

Authors

CEJPEK, Pavel (203 Czech Republic, guarantor), Petr KUGLÍK (203 Czech Republic), Renata VESELSKÁ (203 Czech Republic), Eva NEČESALOVÁ (203 Czech Republic), Martina PEŠÁKOVÁ (203 Czech Republic), Vladimíra VRANOVÁ (203 Czech Republic), Tomáš LOJA (703 Slovakia), Jiřina RELICHOVÁ (203 Czech Republic), Petr KRUPA (203 Czech Republic), Jaroslav HORKÝ (203 Czech Republic) and Zenon STARČUK (203 Czech Republic)

Edition

11th European Workshop on Cytogenetics and Molecular Genetics of Solid Tumors, 2008

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14310/08:00027348

Organization unit

Faculty of Science

UT WoS

000251574500064

Keywords in English

Glioblastoma ;Molecular characteristics

Tags

International impact, Reviewed
Změněno: 6/4/2010 14:14, prof. RNDr. Renata Veselská, Ph.D., M.Sc.

Abstract

V originále

The significance of cytogenetics and molecular genetics for glioblastoma diagnostics as related to therapy and prognosis

In Czech

Význam cytogenetiky a molekulární genetiky pro diagnozu glioblastomu ve vztahu k terapii a prognóze

Links

MSM0021622415, plan (intention)
Name: Molekulární podstata buněčných a tkáňových regulací
Investor: Ministry of Education, Youth and Sports of the CR, Molecular basis of cell and tissue regulations
OC B19.001, research and development project
Name: Genová diagnostika a terapie multiformního glioblastomu (Acronym: COST)
Investor: Ministry of Education, Youth and Sports of the CR, Gene Diagnostics and Therapy of Multiform Glioblastoma